These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 29651974)
1. Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation. Salek N; Vosoghi S; Arani SS; Samani AB; Mehrabi M; Maraghe MG Curr Radiopharm; 2018; 11(2):116-122. PubMed ID: 29651974 [TBL] [Abstract][Full Text] [Related]
2. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation. Salek N; Shamsaei M; Ghannadi Maragheh M; Shirvani Arani S; Bahrami Samani A J Appl Clin Med Phys; 2016 Nov; 17(6):128-139. PubMed ID: 27929488 [TBL] [Abstract][Full Text] [Related]
3. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431 [TBL] [Abstract][Full Text] [Related]
4. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical. Simón J; Frank RK; Crump DK; Erwin WD; Ueno NT; Wendt RE Nucl Med Biol; 2012 Aug; 39(6):770-6. PubMed ID: 22459336 [TBL] [Abstract][Full Text] [Related]
5. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP. Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266 [TBL] [Abstract][Full Text] [Related]
6. 212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy. Hassfjell SP; Bruland OS; Hoff P Nucl Med Biol; 1997 Apr; 24(3):231-7. PubMed ID: 9228657 [TBL] [Abstract][Full Text] [Related]
7. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276 [TBL] [Abstract][Full Text] [Related]
9. Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP. Salek N; Shirvani Arani S; Bahrami Samani A; Vosoghi S; Mehrabi M Australas Phys Eng Sci Med; 2018 Mar; 41(1):69-79. PubMed ID: 29260406 [TBL] [Abstract][Full Text] [Related]
10. A "mix-and-use" approach for formulation of human clinical doses of Chakraborty S; Vimalnath KV; Rajeswari A; Chakravarty R; Sarma HD; Radhakrishnan E; Kamaleshwaran K; Shinto AS; Dash A J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391 [TBL] [Abstract][Full Text] [Related]
11. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs. Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776 [TBL] [Abstract][Full Text] [Related]
12. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641 [TBL] [Abstract][Full Text] [Related]
14. Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical. Fathi F; Moghaddam-Banaem L; Shamsaei M; Samani A; Maragheh MG J Med Phys; 2015; 40(3):156-64. PubMed ID: 26500402 [TBL] [Abstract][Full Text] [Related]
15. 90Sr-90Y biokinetics at incorporation determine the radiation burden to bone marrow. Stevenson AF Indian J Exp Biol; 2000 Mar; 38(3):222-4. PubMed ID: 10927862 [TBL] [Abstract][Full Text] [Related]
16. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation. Chakraborty S; Das T; Banerjee S; Chaudhari PR; Sarma HD; Venkatesh M; Pillai MR Nucl Med Commun; 2004 Dec; 25(12):1169-76. PubMed ID: 15640774 [TBL] [Abstract][Full Text] [Related]
17. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. Konijnenberg MW; Bijster M; Krenning EP; De Jong M J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075 [TBL] [Abstract][Full Text] [Related]
18. Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation. Pedraza-López M; Ferro-Flores G; de Murphy CA; Tendilla JI; Villanueva-Sánchez O Nucl Med Commun; 2004 Jun; 25(6):615-21. PubMed ID: 15167523 [TBL] [Abstract][Full Text] [Related]
19. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution. Sohaib M; Ahmad M; Jehangir M; Perveen A Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750 [TBL] [Abstract][Full Text] [Related]
20. Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases. Vimalnath KV; Rajeswari A; Sarma HD; Dash A; Chakraborty S J Labelled Comp Radiopharm; 2019 Apr; 62(4):178-189. PubMed ID: 30663098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]